TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection
GS-US-528-6727
Phase 3 small_molecule active
Quick answer
TENOFOVIR DISOPROXIL AND EMTRICITABINE , Sunlenca 300 mg film-coated tablets, Sunlenca 464 mg solution for injection for Human Immunodeficiency Virus (HIV-1) infection is a Phase 3 program (small_molecule) at Gilead Sciences International Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Gilead Sciences International Limited
- Indication
- Human Immunodeficiency Virus (HIV-1) infection
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active